Equities

OSE Immunotherapeutics SA

OSE Immunotherapeutics SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)7.71
  • Today's Change-0.39 / -4.81%
  • Shares traded212.29k
  • 1 Year change+109.23%
  • Beta0.6105
Data delayed at least 15 minutes, as of May 27 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

OSE Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company, engaged in clinical stage biotechnological sector. It develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The Company's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. It provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

  • Revenue in EUR (TTM)2.23m
  • Net income in EUR-23.00m
  • Incorporated2004
  • Employees62.00
  • Location
    OSE Immunotherapeutics SA22, boulevard Benoni GoullinNANTES 44200FranceFRA
  • Phone+33 228291010
  • Fax+33 141219107
  • Websitehttps://ose-immuno.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Eurofins-Cerep SA46.17m9.21m109.96m233.0011.941.839.822.381,826.411,826.419,160.0011,939.290.68141.666.04220,892.0013.6015.1916.0618.9485.5767.3019.9519.725.17112.420.000050.0014.4514.3017.0924.52----
AB Science SA970.00k-11.99m110.14m89.00------113.55-0.2492-0.24920.0195-0.41110.03930.96724.89---48.58-65.95-316.31-515.1760.5288.41-1,235.57-1,148.981.02-12.17----1.25-10.6311.97---6.55--
Maat Pharma SA2.23m-19.72m111.18m50.00--4.54--49.90-1.73-1.730.1961.760.05084.844.1644,560.00-44.99-35.49-58.93-42.9874.28---884.96-1,157.542.76-49.610.4075--55.80---43.78--30.30--
DBV Technologies SA14.50m-67.04m120.00m104.00--0.9252--8.27-0.7066-0.70660.15251.340.0732--1.18139,446.90-33.86-53.18-40.10-65.47--93.62-462.30-1,145.92----0.0388--224.69-1.7124.27---34.47--
Adocia SA2.15m-21.16m130.45m78.00------60.67-1.93-1.930.194-0.49080.07742.627.4427,564.10-76.16-43.08-396.14-72.937.91---984.28-514.531.01-2.072.12---81.22-46.13-206.65---27.60--
Transgene SA7.63m-22.33m134.54m158.00--8.59--17.62-0.2227-0.22270.07590.15530.1368--4.2848,316.46-40.00-24.81-50.27-29.79-----292.48-193.24----0.4764---23.681.5131.94--14.44--
Eurobio Scientific SA130.00m4.84m153.53m137.0034.720.93496.601.180.43150.431511.5916.020.40183.194.31948,927.001.4916.911.8021.5347.1150.953.7223.342.322.810.36660.00-14.8120.80-80.61--20.02--
Inventiva SA17.48m-110.43m172.65m112.00------9.88-2.45-2.450.3854-0.61460.1884--9.18156,044.60-116.84-54.30-207.08-69.98-----620.31-669.970.9524-19.986.96--43.5040.46-103.46---0.33--
Aelis Farma SA9.05m-5.08m173.68m26.00--13.16--19.18-0.3907-0.39070.70190.99570.2765--2.41348,230.80-15.51-24.53-25.59-40.55-----56.09-109.622.47--0.1547--137.70--64.46--37.35--
Ose Immunotherapeutics SA2.23m-23.00m176.32m62.00--7.61--79.17-1.18-1.180.11661.060.0256--3.22---26.46-17.17-33.15-20.55-----1,032.87-94.71---97.810.6659---87.83-38.07-29.52---17.11--
Cellectis SA8.48m-100.92m179.56m235.00--2.30--21.18-1.73-1.620.15341.090.0309--13.7136,070.98-39.24-24.08-60.81-30.69---64.64-1,270.92-308.24---5.080.5429---64.26-15.57-20.55---26.15--
Genfit SA38.18m-28.89m209.42m159.00--3.08--5.49-0.5814-0.58140.76811.360.1961542.003.52240,100.60-14.84-12.57-18.55-15.3094.3294.96-75.69-76.232.94-7.780.5080--43.7038.49-21.82---3.27--
Innate Pharma SA51.90m-7.57m215.90m179.00--4.16--4.16-0.0939-0.09390.64510.6420.2648--5.67289,949.70-3.86-8.83-4.87-12.1194.5093.17-14.59-55.55----0.6408--4.68-8.2786.94--10.50--
Sensorion SA0.00-22.06m237.20m50.00--4.44-----0.2063-0.20630.000.17790.00-------51.64-35.12-71.66-46.97------------0.0794------4.94--126.45--
Data as of May 27 2024. Currency figures normalised to OSE Immunotherapeutics SA's reporting currency: Euro EUR

Institutional shareholders

1.83%Per cent of shares held by top holders
HolderShares% Held
Mandarine Gestion SAas of 29 Feb 2024230.00k1.06%
La Fran�aise Asset Management SASas of 31 Jan 2024110.00k0.51%
Financi�re Arbevel SAas of 30 Dec 202230.48k0.14%
Alphajet Fair Investors SASas of 21 May 202413.00k0.06%
Chaussier Gestion SAas of 28 Mar 202412.00k0.06%
Gestys SAas of 26 Jan 20243.00k0.01%
CATAM Asset Management AGas of 30 Apr 20240.000.00%
More ▼
Data from 31 Jan 2024 - 21 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.